Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

Video

In Partnership With:

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

The benefit with immunotherapy agents is a major positive step in the right direction for this field, Seiwert explains. However, it is also a first step as there is a lot of room for improvement and a hope to cure patients in the metastatic setting. There are reports, though, of patients surviving for a long time after achieving deep or complete responses.

The goal must be to continue this approach and move past minor partial responses, Seiwert says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD